(Q39460202)

12 September 2017

1 reference

title

Gastrointestinal endocrine tumours: medical management (English)

1 reference

12 September 2017

Arnold R

1

1 reference

12 September 2017

Frank M

series ordinal

2

1 reference

12 September 2017

publication date

1 December 1996

1 reference

Bailliere's clinical gastroenterology

12 September 2017

published in

1 reference

12 September 2017

volume

10

1 reference

12 September 2017

issue

4

1 reference

12 September 2017

page(s)

737-759

1 reference

Treatment of liver metastases of carcinoid tumors

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Therapeutic embolisation of the hepatic artery: a review of 75 procedures

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Remission of symptoms in carcinoid syndrome with a new 5-hydroxytryptamine M receptor antagonist

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Liver transplantation for primary and secondary hepatic apudomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Somatostatin analog sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Effects of sandostatin on neuroendocrine tumours of the gastrointestinal system.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Regression of metastatic vipoma with somatostatin analogue SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Comparison of Ranitidine and Cimetidine in the Treatment of Gastric Hypersecretion

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Biochemical and morphological investigations of 30 human insulinomas. Correlation between the tumour content of insulin and proinsulin-like components and the histological and ultrastructural appearance

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of Gastrointestinal Endocrine Tumours with Interferon-α and Octreotide

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of carcinoid syndrome with recombinant interferon alpha-2a.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Gallstones during octreotide therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Liver transplantation for metastatic carcinoid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Use of omeprazole in patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Ketanserin versus placebo in carcinoid syndrome. A clinical controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Life-threatening water intoxication during somatostatin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Recombinant alpha-2 interferon with or without hepatic artery embolization in the treatment of midgut carcinoid tumours. A preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Indomethacin-Responsive Pancreatic Cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Positive somatostatin receptor scintigraphy correlates with the presence of somatostatin receptor subtype 2.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Carcinoids: the association of histologic growth pattern and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

The glucagonoma syndrome and its management

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Escape of the response to a long-acting somatostatin analogue (SMS 201-995) in patients with VIPoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Can inhibition of hormone secretion be associated with endocrine tumour shrinkage?

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Effect of the somatostatin analogue sandostatin (SMS 201-995) on gastrointestinal, pancreatic and biliary function and hormone release in normal men.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Suppression of pancreatic endocrine tumour secretion by long-acting somatostatin analogue

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Clinicopathological study of pancreatic and ganglioneuroblastoma tumours secreting vasoactive intestinal polypeptide (vipomas).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Use of long-acting somatostatin analog SMS 201-995 in patients with pancreatic islet cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Long-term efficacy and safety of omeprazole in patients with Zollinger-Ellison syndrome: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Currently used doses of omeprazole in Zollinger-Ellison syndrome are too high

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Reflux esophagitis in patients with Zollinger-Ellison syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Streptozocin Alone Compared with Streptozocin plus Fluorouracil in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Therapy of metastatic carcinoid tumor and the malignant carcinoid syndrome with recombinant leukocyte A interferon

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Streptozocin–Doxorubicin, Streptozocin–Fluorouracil, or Chlorozotocin in the Treatment of Advanced Islet-Cell Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Evaluation of a euglycaemic clamp procedure as a diagnostic test in insulinoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Beneficial Effect of Oral Lithium Carbonate in the Treatment of Pancreatic Cholera Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

The effect of a serotonin antagonist (UML 491) in carcinoid disease

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

THE CARDIAC DISEASE ASSOCIATED WITH THE CARCINOID SYNDROME (CARCINOID HEART DISEASE)

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Octreotide (SMS 201-995) in the treatment of metastatic glucagonoma: report of one case and review of the literature.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Effect of somatostatin on diarrhea and on small intestinal water and electrolyte transport in a patient with pancreatic cholera

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of the carcinoid syndrome with the longacting somatostatin analogue lanreotide: a prospective study in 39 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Pancreatic cholera syndrome: effect of a synthetic somatostatin analog on intestinal water and ion transport.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Regression of liver metastases in patient with gastrin-secreting tumour treated with SMS 201-995

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Serotonin now: clinical implications of inhibiting its synthesis with para-chlorophenylalanine

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Doxorubicin plus cisplatin in the treatment of apudomas

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Surgical management for carcinoid tumors of small bowel, appendix, colon, and rectum

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Use of somatostatin analog in management of carcinoid syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Prospective study of chemotherapy in patients with metastatic gastrinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Tumor regression of an ileal carcinoid under the treatment with the somatostatin analogue SMS 201-995.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Treatment of patients with pancreatic endocrine tumours using a new long-acting somatostatin analogue symptomatic and peptide responses

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

Cloning, functional expression and pharmacological characterization of a fourth (hSSTR4) and a fifth (hSSTR5) human somatostatin receptor subtype

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3528%2896%2990021-4

7 January 2021

10.1016/S0950-3528(96)90021-4

Identifiers

DOI

1 reference

12 September 2017

1 reference